Ascom Wireless Solutions to highlight Middle East and Asia presence at Arab Health 2016 exhibition
17.1.2016 04:00 | Business Wire
Ascom Wireless Solutions, one of the world’s leading providers of mission-critical wireless communication solutions for healthcare, will use its presence at the upcoming Arab Health 2016 event to underscore its commitment and involvement in the Middle East and Asia.
“Arab Health 2016 is our showcase event of the year for the rapidly growing Middle East market,” says Ahmad Al Jassim, Managing Director Ascom Middle East. “We have good news to share, such as how our innovative solutions are helping hospitals become state-of-the-art organizations offering high levels of care bringing them closer to the people that really matter. There’s also the news that Ascom is committed to focusing on healthcare by providing integrated workflow intelligence solutions, and how we are working with our partners to achieve this.”
Ascom’s strategic focus on healthcare calls for the sector to generate at least 75% of the company’s annual revenue by 2020. “It’s an ambitious goal,” says Al Jassim. “But with a track record that includes thousands of healthcare installations, we are well placed to reach this objective. Our healthcare customers in the Middle East and Asia stand to gain from our deep understanding of the sector and the tremendous challenges they face.”
The Ascom space at Arab Health 2016, stand S3D70, is a 64m2 display, meeting and multi-media area. “This is to date the company’s biggest presence at the exhibition,” adds Al Jassim, “and will help healthcare decision-makers really understand and experience our solutions’ benefits.”
More than 4,000 companies are due to exhibit at Arab Health 2016, to be held January 25-28 at the Dubai International Conference and Exhibition Centre. Says Al Jassim in conclusion: “With 130,000-plus healthcare professionals from 163 countries expected to visit, Arab Health 2016 is an ideal showcase for our innovative solutions, and for meeting all our old and new friends.”
For more information visit www.ascom.com/ws
ABOUT ASCOM WIRELESS SOLUTIONS
Ascom Wireless Solutions (www.ascom.com/ws) is a leading provider of innovative communication solutions providing integrated workflow intelligence for hospitals, senior care, and independent living, and other business areas where mission-critical communication is essential. Approximately 100 000 systems are installed globally. The company offers a broad range of voice and professional messaging solutions, creating value for customers by supporting and optimizing their mission-critical communication processes. The solutions are based on Cellular, VoWiFi, IP-DECT, Nurse call and Paging technologies, smartly integrated via Ascom Unite into existing enterprise systems. The company has subsidiaries in 13 countries and 1,200 employees worldwide. Founded in 1955 and based in Göteborg, Sweden, Ascom Wireless Solutions is part of the Ascom Group, listed on the Swiss Stock Exchange ASCN:SIX).
Ascom Wireless Solutions
Hiral Chavda, Marketing Manager Growth Markets
Phone: +46 31 55 91 75
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00 | Pressemelding
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom